[go: up one dir, main page]

DK0831769T3 - Hidtil ukendte anvendelser af thyroideahormoner eller thyroideahormon-lignende forbindelser - Google Patents

Hidtil ukendte anvendelser af thyroideahormoner eller thyroideahormon-lignende forbindelser

Info

Publication number
DK0831769T3
DK0831769T3 DK96924268T DK96924268T DK0831769T3 DK 0831769 T3 DK0831769 T3 DK 0831769T3 DK 96924268 T DK96924268 T DK 96924268T DK 96924268 T DK96924268 T DK 96924268T DK 0831769 T3 DK0831769 T3 DK 0831769T3
Authority
DK
Denmark
Prior art keywords
thyroid hormone
thyroid
compound
concentration
compounds
Prior art date
Application number
DK96924268T
Other languages
English (en)
Inventor
Anders Vahlquist
Thomas N Lavin
Original Assignee
Karobio Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23913014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0831769(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Karobio Ab filed Critical Karobio Ab
Application granted granted Critical
Publication of DK0831769T3 publication Critical patent/DK0831769T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • A61K31/055Phenols the aromatic ring being substituted by halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/004Aftersun preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/06Preparations for care of the skin for countering cellulitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Cosmetics (AREA)
  • Furan Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK96924268T 1995-06-07 1996-06-07 Hidtil ukendte anvendelser af thyroideahormoner eller thyroideahormon-lignende forbindelser DK0831769T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48169895A 1995-06-07 1995-06-07
PCT/US1996/009975 WO1996040048A2 (en) 1995-06-07 1996-06-07 Novel uses for thyroid hormones or thyroid hormone-like compounds

Publications (1)

Publication Number Publication Date
DK0831769T3 true DK0831769T3 (da) 2004-02-23

Family

ID=23913014

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96924268T DK0831769T3 (da) 1995-06-07 1996-06-07 Hidtil ukendte anvendelser af thyroideahormoner eller thyroideahormon-lignende forbindelser

Country Status (10)

Country Link
EP (2) EP0831769B2 (da)
JP (1) JPH11508241A (da)
AT (1) ATE251887T1 (da)
AU (1) AU6476996A (da)
CA (1) CA2223720C (da)
DE (1) DE69630380T8 (da)
DK (1) DK0831769T3 (da)
ES (1) ES2208753T5 (da)
PT (1) PT831769E (da)
WO (1) WO1996040048A2 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380255B1 (en) * 1995-06-07 2002-04-30 Karo Bio Ab Treatment for dermal skin atrophy using thyroid hormone compounds or thyroid hormone-like compounds
ES2156361T5 (es) * 1996-03-29 2012-12-26 Keyvest Gmbh Cosmético o bien composición cosmética para el alisado y la tersura de la piel en el caso de tejido adiposo afectado, en especial en el caso de la "celulitis"
WO1998007435A1 (en) * 1996-08-20 1998-02-26 The Regents Of The University Of California Eye treatments using synthetic thyroid hormone compositions
GB9828442D0 (en) 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
US6740680B1 (en) * 1999-04-26 2004-05-25 Becton Pharma, Inc. Pharmaceutical compositions to tetrac and methods of use thereof
JP2002542284A (ja) * 1999-04-26 2002-12-10 ダンフォース,エリオット,ジュニア テトラックの薬学組成物およびその使用方法
BR0013272B1 (pt) * 1999-08-13 2013-10-15 Uso de um inibidor de aromatase esteroidal
US6638977B1 (en) 1999-11-19 2003-10-28 Corvas International, Inc. Plasminogen activator inhibitor antagonists
AU1624801A (en) * 1999-11-19 2001-05-30 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
FI107018B (fi) * 2000-04-06 2001-05-31 Ipsat Therapies Oy Dermatologinen käyttö ja valmiste
US7163918B2 (en) 2000-08-22 2007-01-16 New River Pharmaceuticals Inc. Iodothyronine compositions
JP2005507381A (ja) 2001-08-24 2005-03-17 カロ バイオ アクチェブラーグ 心臓障害および代謝障害の治療のための主要環置換甲状腺受容体アンタゴニスト
US7321065B2 (en) * 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
EP2335694B1 (en) 2003-09-15 2018-06-13 NanoPharmaceuticals LLC Thyroid hormone analogs and methods of use
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
US8071134B2 (en) 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
JP2007512359A (ja) 2003-11-19 2007-05-17 メタバシス・セラピューティクス・インコーポレイテッド 新規なリン含有甲状腺ホルモン様物質
CA2606499C (en) 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US20100209382A1 (en) 2005-09-16 2010-08-19 Ordway Research Institute, Inc. Polyphenol Conjugates as RGD-Binding Compounds and Methods of Use
WO2007059039A1 (en) * 2005-11-11 2007-05-24 Oregon Health & Science University Thyroxine derivatives for preconditioning against stroke
EP2018186A2 (en) * 2006-04-11 2009-01-28 Ordway Research Institute, Inc. Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
CA2673133C (en) 2006-12-22 2016-08-30 Clf Medical Technology Acceleration Program, Inc. Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
WO2010120506A1 (en) 2009-03-31 2010-10-21 Ordway Research Institute, Inc. Combination treatment of cancer with cetuximab and tetrac
CA2765792C (en) 2009-06-17 2017-03-28 Ordway Research Institute, Inc. Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
WO2015074050A1 (en) 2013-11-18 2015-05-21 Nanopharmaceuticals Llc Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereof
BR112017010778A2 (pt) 2014-11-25 2018-01-09 Trophea Dev Ab tratamento de atrofia de pele com uma combinação de ácido triiodotiroacético (triac) e desidroepiandrosterona (dhea)
CA3026504A1 (en) 2016-06-07 2017-12-14 Nanopharmaceuticals, Llc Non-cleavable polymer conjugated with .alpha..nu..beta.3 integrin thyroid antagonists
WO2018094265A2 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
CN110996966A (zh) 2017-06-05 2020-04-10 维京治疗公司 用于治疗纤维化的组合物
KR20200138283A (ko) 2018-03-22 2020-12-09 바이킹 테라퓨틱스 인코포레이티드 결정질 형태, 및 결정질 형태의 화합물을 제조하는 방법
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE515812A (da) *
GB782745A (en) * 1953-08-13 1957-09-11 Arthur Alfred Hellbaum Improvements in or relating to pharmaceutical compositions
GB859546A (en) * 1956-05-29 1961-01-25 Arthur Alfred Hellbaum Composition for treatment of the skin
US3198702A (en) * 1960-03-17 1965-08-03 Arthur A Hellbaum Method for treating skin burns
FR3111M (fr) * 1963-12-02 1965-02-08 Rech S Pharma Et Scient Médicament a base de dérivé de cystéine.
FR6656M (da) * 1967-02-23 1969-01-27
FR2139748B1 (da) * 1971-06-03 1974-08-30 Theranol Lab
FR2160258A1 (en) * 1971-11-16 1973-06-29 Egema Triiodothyroalkanoic acid derivs - for treating lipid overload and celluitis
FR2142675A1 (en) * 1971-06-23 1973-02-02 Egema Sa Triiodothyroalkanoic acid derivs - for treating lipid overload and celluitis
GB1400851A (en) * 1971-06-23 1975-07-16 Egema Sa Triidothyroalkyl compounds their method of preparation and therapeutical compositions containing such compounds
FR2153202A1 (en) * 1971-09-24 1973-05-04 Ind Chimique Triiodothyroacetic acid salts prepn - with metals and organic bases
FR2197577A1 (en) * 1972-08-30 1974-03-29 Ind Chimi Ue Sa Hypocholesterolaemic, antiatheroma agents - 3,5-diiodo-4-(3-iodo-4-alkoxy-carbonyl phenoxy) phenylalkanoic acids, esters and salts
CH622703A5 (en) * 1976-06-10 1981-04-30 Berema Sa Therapeutic compositions for treating deposits of excess fat and infiltrates causing cellulite
FR2356427A2 (fr) * 1976-07-02 1978-01-27 Ana Laboratoires Nouveaux medicaments pour le traitement des surcharges lipidiques et de la cellulite
FR2357246A1 (fr) * 1976-07-09 1978-02-03 Martinez Gerard Nouvelles compositions therapeutiques douees d'activite anti-inflammatoire, antalgique et anti-cellulitique
GB1587638A (en) * 1977-06-03 1981-04-08 Berema Sa Iodophenoxyphenylalkenoic acid derivatives and pharmaceutical preparations containing them
RO76691A2 (ro) * 1979-04-02 1981-08-30 Intreprinderea De Produse Cosmetice "Farmec",Ro Crema nutritiva impotriva ridurilor
CH642851A5 (en) * 1980-02-13 1984-05-15 Berema Sa Medicinal compositions for the treatment of cellulite
FR2501505A1 (fr) * 1981-03-11 1982-09-17 Ana Laboratoires Nouveaux medicaments destines au traitement des hyperlipidemies et hypercholesterolemies a base d'acide 3,5-diiodo-3'-isopropyl-thyroacetique
FI107018B (fi) * 2000-04-06 2001-05-31 Ipsat Therapies Oy Dermatologinen käyttö ja valmiste

Also Published As

Publication number Publication date
JPH11508241A (ja) 1999-07-21
ATE251887T1 (de) 2003-11-15
AU6476996A (en) 1996-12-30
EP0831769B2 (en) 2008-07-23
CA2223720A1 (en) 1996-12-19
PT831769E (pt) 2004-02-27
ES2208753T3 (es) 2004-06-16
EP1398024A3 (en) 2004-12-15
WO1996040048A3 (en) 1997-11-13
DE69630380D1 (de) 2003-11-20
WO1996040048A2 (en) 1996-12-19
EP1398024A2 (en) 2004-03-17
DE69630380T2 (de) 2004-08-12
DE69630380T3 (de) 2009-04-30
EP0831769B1 (en) 2003-10-15
DE69630380T8 (de) 2009-08-06
EP0831769A2 (en) 1998-04-01
ES2208753T5 (es) 2009-02-01
CA2223720C (en) 2008-12-30

Similar Documents

Publication Publication Date Title
DK0831769T3 (da) Hidtil ukendte anvendelser af thyroideahormoner eller thyroideahormon-lignende forbindelser
Johnson et al. Synthesis and characterization of a highly potent and effective antagonist of retinoic acid receptors
WO1994012880A3 (en) Rxr homodimer formation and bridged bicyclic aromatic compounds and their use in modulating gene expression
AR062931A2 (es) Compuestos que se enlazan a y activan un receptor de la trombopoyetina , composicones farmaceuticas que los contienen y su uso para la preparacion de medicamentos
ATE289998T1 (de) Synthese und verwendung von retinoiden mit negativen hormonellen und/oder antagonistischen wirkungen
BR9810378A (pt) Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero
BR9809189A (pt) Compostos adequados para liberação controlada do hormÈnio gnrh e seus análogos
DE69325130D1 (de) N-sulfonyl-2-oxoindol-derivate mit einer affinität für die vasopressin und/oder ocytocin rezeptoren
NO20003552D0 (no) Progesteron-agonistforbindelser, farmasøytiske sammensetninger inneholdende disse og anvendelsen av forbindelsen, samt en fremgangsmÕte for bestemmelse av tilstedeværelse av steroidreseptorer, ligand-steroidreseptorkomplekser og en fremgangsmÕte
DE68920128D1 (de) Sulfonsäure-substituierte aromatische Steroide als 5-Alpha-Reduktase-Inhibitoren.
GEP19991704B (en) Carbon Derivatives, Method for Its Production, Compositions Based Thereon
BR0013597A (pt) Compostos e métodos moduladores de receptor de androgênio
NL300017I2 (nl) Gesubstitueerde androsta-1,4-dieen-3,17-dionen, alsmede farmaceutische preparaten die dergelijke verbindingen bevatten.
ES2040743T3 (es) Compuestos conjugados comprendiendo un ligando macrociclico y un anticuerpo.
DE69519496D1 (de) Zusammensetzungen, welche ein RAR alpha spezifischer Liganden und mindestens eine Fettsäure enthalten
ES8608535A1 (es) Procedimiento para preparar una composicion para el tratamiento topico de acne
BR9709062A (pt) Composto, composição farmacêutica, e, uso de um composto.
MX9602563A (es) Compuestos carbociclicos.
NZ266314A (en) Various indane-2-carboxylic acid derivatives substituted by (hetero)aryl-containing moieties and various other indane derivatives as endothelian receptor antagonists and pharmaceutical compositions
LV10949A (lv) Aizvietoti 4-fenil-4piperidinkarboksamidi to iegusanas panemiens farmaceitiska kompozicija
DE69610387D1 (de) Biphenylverbindungen, Verfahren zu ihrer Herstellung und Intermediate für dieses Verfahren, ihre Verwendung als 5-alpha-Reduktase-Inhibitoren und diese enthaltende pharmazeutische Zusammensetzungen
DE69621076D1 (de) Verwendung von spezifischen RXR-Rezeptorliganden
EP0378197A3 (de) Vitamin-B12-Bestimmung
FI953567A0 (fi) Vähintään yhden RXRs-spesifisen ligandin ja vähintään yhden RAR-alfa-spesifisen ligandin synergeettiseen seokseen perustuvat uudenlaiset koostumukset sekä niiden käyttö
ATE154031T1 (de) 8-en-19, 11 beta-überbrückte steroide, deren herstellung und diese enthaltende pharmazeutische präparate